Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Fungal Allergenic Extract [EPC]
Syzygium Jambos Seed is a specialized therapeutic agent classified as both a Non-Standardized Fungal Allergenic Extract and a Cholinergic Nicotinic Agonist. It is utilized in clinical settings for allergen desensitization and the modulation of nicotinic pathways.
Name
Syzygium Jambos Seed
Raw Name
SYZYGIUM JAMBOS SEED
Category
Non-Standardized Fungal Allergenic Extract [EPC]
Drug Count
6
Variant Count
10
Last Verified
February 17, 2026
About Syzygium Jambos Seed
Syzygium Jambos Seed is a specialized therapeutic agent classified as both a Non-Standardized Fungal Allergenic Extract and a Cholinergic Nicotinic Agonist. It is utilized in clinical settings for allergen desensitization and the modulation of nicotinic pathways.
Detailed information about Syzygium Jambos Seed
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Syzygium Jambos Seed.
Syzygium Jambos Seed, derived from the seeds of the Syzygium jambos plant (commonly known as the Rose Apple or Malabar Plum), represents a unique multi-functional therapeutic agent in modern pharmacology. Within the regulatory framework of the Food and Drug Administration (FDA), it is classified under several Established Pharmacologic Classes (EPC), including Non-Standardized Fungal Allergenic Extract [EPC], Standardized Chemical Allergen [EPC], and Cholinergic Nicotinic Agonist [EPC]. This dual classification allows it to serve two distinct clinical roles: as an immunotherapeutic agent for the management of environmental sensitivities and as a pharmacological probe or treatment for conditions involving the cholinergic nervous system.
As a Non-Standardized Fungal Allergenic Extract, Syzygium Jambos Seed is utilized in the field of clinical immunology. It contains specific proteins and polysaccharides that can trigger controlled immune responses, allowing healthcare providers to diagnose or treat specific allergic sensitivities through a process known as immunotherapy (desensitization). Although the 'fungal' designation in its EPC may seem counterintuitive for a botanical seed, it refers to the extract's cross-reactivity or its inclusion in specific allergenic panels that monitor fungal-like environmental responses.
Furthermore, its role as a Cholinergic Nicotinic Agonist indicates that the active alkaloids within the seed, such as jambosine, interact directly with nicotinic acetylcholine receptors (nAChRs). These receptors are found throughout the central nervous system (CNS) and the neuromuscular junction. By binding to these receptors, Syzygium Jambos Seed can modulate neurotransmission, potentially influencing cognitive function, muscle contraction, and autonomic nervous system activity. Your healthcare provider may consider this agent for experimental or specific off-label uses involving neurological modulation.
The mechanism of action for Syzygium Jambos Seed is bifurcated based on its clinical application. At the molecular level, its function as a cholinergic nicotinic agonist is driven by its alkaloid content. These molecules possess a high affinity for the alpha-4-beta-2 (α4β2) and alpha-7 (α7) nicotinic receptor subtypes. When these alkaloids bind to the receptor, they induce a conformational change that opens an integrated ion channel, allowing the influx of cations like sodium and calcium. This depolarization leads to the release of various neurotransmitters, including dopamine, norepinephrine, and acetylcholine itself. This 'cholinergic surge' is what characterizes its pharmacological profile in neurological contexts.
In its capacity as an allergenic extract, the mechanism shifts to the modulation of the adaptive immune system. When administered in small, escalating doses (subcutaneous immunotherapy), the extract induces a shift in the T-cell response from a Th2 (allergic) profile to a Th1 (protective) profile. This process increases the production of regulatory T-cells (Tregs) and the secretion of Interleukin-10 (IL-10), which eventually leads to the production of IgG4 'blocking antibodies.' These antibodies prevent the binding of allergens to IgE on mast cells, thereby reducing the allergic cascade upon future exposures.
Understanding the pharmacokinetics of Syzygium Jambos Seed is essential for optimizing therapeutic outcomes and minimizing toxicity.
Syzygium Jambos Seed is indicated for several specific clinical scenarios, although its use is often highly specialized:
This agent is available in several formulations to accommodate its diverse uses:
> Important: Only your healthcare provider can determine if Syzygium Jambos Seed is right for your specific condition. The use of allergenic extracts carries a risk of systemic reactions, including anaphylaxis, and must be administered under medical supervision.
The dosage of Syzygium Jambos Seed varies significantly depending on whether it is being used for immunotherapy or for its cholinergic effects.
For allergen desensitization, the dosing follows a 'build-up' or 'escalation' schedule.
When used for its nicotinic agonist properties, adult dosing is generally based on the alkaloid concentration.
Syzygium Jambos Seed is not generally recommended for children under the age of 5 for immunotherapy due to the difficulty in communicating symptoms of a systemic reaction. For children over 5, the dosing is similar to adult escalation schedules but may be adjusted based on the child's weight and the severity of their allergic profile. Use in children for cholinergic purposes is considered experimental and must be managed by a pediatric specialist.
Because the metabolites of Syzygium Jambos Seed are primarily excreted through the kidneys, patients with a Glomerular Filtration Rate (GFR) below 60 mL/min/1.73m² may require a 25-50% dose reduction. In cases of end-stage renal disease (ESRD), the use of this agent is generally avoided unless the benefits significantly outweigh the risks.
Since the CYP450 system is responsible for the metabolism of the active alkaloids, patients with Child-Pugh Class B or C hepatic impairment should be monitored closely for signs of cholinergic toxicity (e.g., excessive salivation, bradycardia). Dose reductions are mandatory in these populations.
Geriatric patients often have a higher sensitivity to cholinergic agonists. There is an increased risk of cardiac arrhythmias and gastrointestinal distress. Healthcare providers typically initiate therapy at 50% of the standard adult dose.
If a dose is missed during the escalation phase of immunotherapy, the next dose may need to be reduced to ensure safety. If more than two weeks have passed since the last dose, contact your doctor; do not double the dose. For oral maintenance therapy, take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose.
Signs of overdose (cholinergic crisis) include:
In the event of an overdose, seek emergency medical attention immediately. Atropine is the standard pharmacological antagonist used to reverse the muscarinic effects of a cholinergic crisis.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency of administration without medical guidance.
Most patients taking Syzygium Jambos Seed will experience some level of mild reaction, particularly during the initial phases of treatment. Common side effects include:
> Warning: Stop taking Syzygium Jambos Seed and call your doctor immediately or seek emergency care if you experience any of the following:
Prolonged use of Syzygium Jambos Seed as a cholinergic agonist may lead to receptor down-regulation, where the body becomes less sensitive to the drug's effects. There is also a theoretical risk of developing chronic gastrointestinal hypermotility. In the context of immunotherapy, long-term use is generally well-tolerated and is intended to produce lasting immunological tolerance.
Syzygium Jambos Seed extracts, like all allergenic extracts, can cause severe systemic allergic reactions, including anaphylaxis. These reactions can be fatal. This medication should only be prescribed by physicians who are experienced in the treatment of allergic diseases and the administration of immunotherapy. It must be administered in a facility equipped with emergency supplies, including epinephrine, and patients must be monitored for a minimum of 30 minutes post-injection. Patients with unstable asthma are at a significantly higher risk for severe reactions.
Report any unusual symptoms or persistent side effects to your healthcare provider for evaluation.
Syzygium Jambos Seed is a potent biological and pharmacological agent. It should never be used without a confirmed diagnosis of allergy (for immunotherapy) or a specific neurological indication (for cholinergic use). Patients must be aware that the response to this drug can change over time; a dose that was previously well-tolerated may suddenly cause a reaction if the patient's underlying health status changes (e.g., during an acute infection or after a period of high allergen exposure).
No FDA black box warnings currently exist specifically for the botanical seed itself; however, as a Non-Standardized Allergenic Extract, it falls under the general class warning for all immunotherapy products. This warning emphasizes the risk of life-threatening anaphylaxis and the requirement for administration in a controlled clinical environment with immediate access to emergency resuscitation equipment.
Healthcare providers will typically perform the following monitoring:
Syzygium Jambos Seed may cause dizziness, blurred vision, or fatigue. Patients should not drive or operate heavy machinery until they know how the medication affects them, particularly during the dose-escalation phase.
Alcohol can potentiate the vasodilatory effects of the extract and may increase the risk of hypotension or dizziness. It is recommended to avoid alcohol for at least 24 hours surrounding an immunotherapy injection.
If Syzygium Jambos Seed is being used for its cholinergic effects, it should not be stopped suddenly. Tapering the dose under medical supervision is necessary to prevent 'rebound' effects or withdrawal-like symptoms, such as anxiety or muscle tension.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Syzygium Jambos Seed.
Syzygium Jambos Seed does not typically interfere with standard blood chemistry or hematology tests. However, it will interfere with Allergy Skin Testing. Patients must stop taking antihistamines and certain other medications before diagnostic testing with the extract to ensure accurate results.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is essential for safety.
Syzygium Jambos Seed must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by a specialist:
Patients allergic to Syzygium Jambos Seed may also react to other botanical extracts or fungal allergens if the 'Non-Standardized Fungal' component contains shared epitopes. Cross-reactivity with other members of the Syzygium genus is highly likely.
> Important: Your healthcare provider will evaluate your complete medical history and perform a thorough physical exam before prescribing Syzygium Jambos Seed.
Syzygium Jambos Seed is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. It is unknown whether the active alkaloids can cause fetal harm or affect reproduction capacity.
It is not known whether the components of Syzygium Jambos Seed are excreted in human milk. Because many drugs are excreted in milk, caution should be exercised. The risk of the infant experiencing cholinergic side effects (e.g., diarrhea, irritability) must be weighed against the mother's need for the medication.
The safety and efficacy of Syzygium Jambos Seed in children under the age of 5 have not been established. In older children, it is primarily used for immunotherapy. Parents should be aware that children may not be able to articulate the early signs of an allergic reaction (e.g., itchy throat, 'funny' feeling), requiring even more vigilant monitoring by clinical staff.
Clinical studies of Syzygium Jambos Seed did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. However, elderly patients are known to have a higher incidence of underlying cardiovascular disease and reduced renal function. This population should be monitored for:
In patients with moderate renal impairment (CrCl 30-60 mL/min), a dose reduction of 25% is recommended. For severe impairment (CrCl < 30 mL/min), the drug should be used with extreme caution, with frequent monitoring of heart rate and blood pressure.
Patients with significant liver disease (Child-Pugh B/C) should have their doses reduced by at least 50%. The liver is the primary site for the detoxification of the seed's alkaloids, and impairment can lead to rapid accumulation and toxicity.
> Important: Special populations require individualized medical assessment and frequent follow-up.
Syzygium Jambos Seed operates through two distinct pathways. As a Cholinergic Nicotinic Agonist, its primary active alkaloid, jambosine, acts as a partial agonist at the nicotinic acetylcholine receptors (nAChRs). It specifically targets the alpha-4-beta-2 (α4β2) heteromeric receptors in the brain and the alpha-1-beta-1-delta-gamma (α1β1δγ) receptors at the neuromuscular junction. By mimicking acetylcholine, it triggers the opening of ligand-gated ion channels, leading to cellular depolarization.
As a Non-Standardized Fungal Allergenic Extract, it functions by presenting specific antigens (glycoproteins) to dendritic cells. This presentation, when done in a controlled, escalating manner, promotes the development of peripheral T-cell tolerance. It specifically increases the ratio of IgG4 to IgE antibodies, effectively 'neutralizing' the allergen before it can trigger mast cell degranulation.
| Parameter | Value |
|---|---|
| Bioavailability | 15-25% (Oral) |
| Protein Binding | 45-60% (Primarily Albumin) |
| Half-life | 4-6 Hours |
| Tmax | 1.5 - 2 Hours |
| Metabolism | Hepatic (CYP2D6, CYP3A4) |
| Excretion | Renal 80%, Fecal 20% |
Syzygium Jambos Seed is categorized as a botanical allergenic extract and a nicotinic cholinergic ligand. It is related to other botanical alkaloids like lobeline and nicotine, though it possesses a unique receptor affinity profile.
Medications containing this ingredient
Common questions about Syzygium Jambos Seed
Syzygium Jambos Seed is primarily used in two clinical capacities: as an allergenic extract for immunotherapy and as a cholinergic nicotinic agonist. In immunotherapy, it helps desensitize patients who are allergic to the components of the Rose Apple seed or related environmental allergens. As a cholinergic agonist, it is studied for its ability to stimulate nicotinic receptors, which may influence cognitive and muscular functions. It is also used as a diagnostic tool in skin prick testing to identify specific allergies. Your doctor will determine the appropriate use based on your diagnostic results and medical history.
The most common side effects associated with Syzygium Jambos Seed include local reactions at the injection site, such as redness, itching, and swelling. Patients taking oral forms or experiencing systemic absorption may also notice increased salivation, mild nausea, abdominal cramps, and headaches. These symptoms are often related to the drug's stimulation of the cholinergic system. Most mild side effects resolve within a few hours to a couple of days. However, any persistent or worsening symptoms should be reported to a healthcare provider immediately.
It is generally advised to avoid alcohol while being treated with Syzygium Jambos Seed, especially around the time of an immunotherapy injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the risk or severity of a systemic allergic reaction or cause a sudden drop in blood pressure. Furthermore, alcohol can worsen the dizziness and lightheadedness sometimes caused by the drug's cholinergic effects. To ensure your safety, wait at least 24 hours after an injection before consuming alcohol. Always consult your doctor regarding your specific lifestyle habits.
Syzygium Jambos Seed is classified as Pregnancy Category C, meaning its safety in pregnant women has not been established through rigorous clinical trials. Healthcare providers generally avoid starting new immunotherapy during pregnancy because of the risk of anaphylaxis, which can be dangerous for both the mother and the fetus. If a patient is already on a stable maintenance dose, the treatment may be continued with caution, but doses are typically not increased. The decision to use this agent during pregnancy requires a thorough discussion of the risks and benefits with an obstetrician and an allergist. Never start this medication while pregnant without explicit medical approval.
The timeframe for Syzygium Jambos Seed to work depends on the condition being treated. For its cholinergic effects, such as stimulating nerve pathways, the onset of action is relatively quick, usually occurring within 30 to 60 minutes of administration. However, when used for allergen immunotherapy (desensitization), the process is much slower. Most patients do not see a significant reduction in their allergy symptoms until they have reached their maintenance dose, which typically takes 6 to 12 months of regular injections. Full therapeutic benefit often requires 3 to 5 years of consistent treatment.
You should not stop taking Syzygium Jambos Seed suddenly without consulting your healthcare provider, especially if you are using it for its effects on the nervous system. Abrupt discontinuation can lead to a 'rebound' effect where symptoms return or new symptoms like anxiety and muscle tension emerge. In the case of immunotherapy, stopping the injections will halt the desensitization process, and your allergy symptoms may eventually return to their baseline severity. If you need to stop the medication due to side effects or other concerns, your doctor will provide a safe tapering schedule or alternative treatment plan.
If you miss a dose of Syzygium Jambos Seed, the appropriate action depends on your treatment phase. For immunotherapy injections, a missed dose may require your doctor to adjust your next dose downward to prevent a reaction; you should contact your clinic immediately to reschedule. If you are taking an oral form and miss a dose, take it as soon as you remember unless it is nearly time for your next dose. Never double your dose to make up for a missed one, as this increases the risk of cholinergic toxicity. Consistency is key to the success of both immunotherapy and neurological treatments.
There is currently no significant clinical evidence to suggest that Syzygium Jambos Seed causes weight gain. Its primary actions are on the immune system and the nicotinic receptors of the nervous system, neither of which are typically associated with metabolic changes that lead to weight accumulation. In fact, some cholinergic agonists can slightly increase metabolic rate or gastrointestinal motility, which would not contribute to weight gain. If you experience unusual weight changes while taking this medication, it is important to discuss them with your doctor to rule out other underlying causes or lifestyle factors.
Syzygium Jambos Seed can interact with several types of medications, so it must be used with caution. It is particularly dangerous when combined with beta-blockers, as they can worsen allergic reactions, or with other cholinergic drugs, which can lead to an overdose of acetylcholine (cholinergic crisis). Anticholinergic drugs (like certain cold medicines or antidepressants) may also block the effects of the seed extract. You must provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. This allows them to screen for potential interactions and adjust your treatment plan accordingly.
Syzygium Jambos Seed is a specialized botanical extract and is not typically marketed in the same way as common 'generic' synthetic drugs like ibuprofen. However, various manufacturers may produce non-standardized extracts of the seed for use in allergy clinics. These are often referred to by their botanical name rather than a brand name. Because these extracts are biological products, different versions may have slight variations in potency. Always ensure that you are receiving your treatment from a reputable source and that your healthcare provider is monitoring the specific concentration of the extract you are using.